Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain

Kristen M. Jaruszewski, Geoffry L. Curran, Suresh K. Swaminathan, Jens T. Rosenberg, Samuel C. Grant, Subramanian Ramakrishnan, Val Lowe, Joseph F. Poduslo, Karunya K. Kandimalla

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries of the cortex and leptomeninges. CAA affects a majority of Alzheimer's disease (AD) patients and is associated with a rapid decline in cognitive reserve. Unfortunately, there is no pre-mortem diagnosis available for CAA. Furthermore, treatment options are few and relatively ineffective. To combat this issue, we have designed nanovehicles (nanoparticles-IgG4.1) capable of targeting cerebrovascular amyloid (CVA) and serving as early diagnostic and therapeutic agents. These nanovehicles were loaded with Gadolinium (Gd) based (Magnevist®) magnetic resonance imaging contrast agents or single photon emission computed tomography (SPECT) agents, such as 125I. In addition, the nanovehicles carry either anti-inflammatory and anti-amyloidogenic agents such as curcumin or immunosuppressants such as dexamethasone, which were previously shown to reduce cerebrovascular inflammation. Owing to the anti-amyloid antibody (IgG4.1) grafted on the surface, the nanovehicles are capable of specifically targeting CVA deposits. The nanovehicles effectively marginate from the blood flow to the vascular wall as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. They demonstrate excellent distribution to the brain vasculature and target CVA, thus providing MRI and SPECT contrast specific to the CVA in the brain. In addition, they also display the potential to carry therapeutic agents to reduce cerebrovascular inflammation associated with CAA, which is believed to trigger hemorrhage in CAA patients.

Original languageEnglish (US)
Pages (from-to)1967-1976
Number of pages10
JournalBiomaterials
Volume35
Issue number6
DOIs
StatePublished - Feb 2014

Fingerprint

Cerebral Amyloid Angiopathy
Nanoprobes
Amyloid
Brain
Alzheimer Disease
Single-Photon Emission-Computed Tomography
Cognitive Reserve
Quartz Crystal Microbalance Techniques
Single photon emission computed tomography
Inflammation
Adventitia
Gadolinium DTPA
Curcumin
Amyloid Plaques
Gadolinium
Immunosuppressive Agents
Nanoparticles
Contrast Media
Dexamethasone
Blood Vessels

Keywords

  • Alzheimer's disease (AD)
  • Brain targeting
  • Cerebrovascular amyloid (CVA)
  • Magnetic resonance imaging (MRI)
  • Nanovehicles
  • Single photon emission computed tomography (SPECT)

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Jaruszewski, K. M., Curran, G. L., Swaminathan, S. K., Rosenberg, J. T., Grant, S. C., Ramakrishnan, S., ... Kandimalla, K. K. (2014). Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials, 35(6), 1967-1976. https://doi.org/10.1016/j.biomaterials.2013.10.075

Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. / Jaruszewski, Kristen M.; Curran, Geoffry L.; Swaminathan, Suresh K.; Rosenberg, Jens T.; Grant, Samuel C.; Ramakrishnan, Subramanian; Lowe, Val; Poduslo, Joseph F.; Kandimalla, Karunya K.

In: Biomaterials, Vol. 35, No. 6, 02.2014, p. 1967-1976.

Research output: Contribution to journalArticle

Jaruszewski, KM, Curran, GL, Swaminathan, SK, Rosenberg, JT, Grant, SC, Ramakrishnan, S, Lowe, V, Poduslo, JF & Kandimalla, KK 2014, 'Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain', Biomaterials, vol. 35, no. 6, pp. 1967-1976. https://doi.org/10.1016/j.biomaterials.2013.10.075
Jaruszewski KM, Curran GL, Swaminathan SK, Rosenberg JT, Grant SC, Ramakrishnan S et al. Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. Biomaterials. 2014 Feb;35(6):1967-1976. https://doi.org/10.1016/j.biomaterials.2013.10.075
Jaruszewski, Kristen M. ; Curran, Geoffry L. ; Swaminathan, Suresh K. ; Rosenberg, Jens T. ; Grant, Samuel C. ; Ramakrishnan, Subramanian ; Lowe, Val ; Poduslo, Joseph F. ; Kandimalla, Karunya K. / Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain. In: Biomaterials. 2014 ; Vol. 35, No. 6. pp. 1967-1976.
@article{d776f5e23e7b45aabfa8b7b68aa03317,
title = "Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain",
abstract = "Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries of the cortex and leptomeninges. CAA affects a majority of Alzheimer's disease (AD) patients and is associated with a rapid decline in cognitive reserve. Unfortunately, there is no pre-mortem diagnosis available for CAA. Furthermore, treatment options are few and relatively ineffective. To combat this issue, we have designed nanovehicles (nanoparticles-IgG4.1) capable of targeting cerebrovascular amyloid (CVA) and serving as early diagnostic and therapeutic agents. These nanovehicles were loaded with Gadolinium (Gd) based (Magnevist{\circledR}) magnetic resonance imaging contrast agents or single photon emission computed tomography (SPECT) agents, such as 125I. In addition, the nanovehicles carry either anti-inflammatory and anti-amyloidogenic agents such as curcumin or immunosuppressants such as dexamethasone, which were previously shown to reduce cerebrovascular inflammation. Owing to the anti-amyloid antibody (IgG4.1) grafted on the surface, the nanovehicles are capable of specifically targeting CVA deposits. The nanovehicles effectively marginate from the blood flow to the vascular wall as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. They demonstrate excellent distribution to the brain vasculature and target CVA, thus providing MRI and SPECT contrast specific to the CVA in the brain. In addition, they also display the potential to carry therapeutic agents to reduce cerebrovascular inflammation associated with CAA, which is believed to trigger hemorrhage in CAA patients.",
keywords = "Alzheimer's disease (AD), Brain targeting, Cerebrovascular amyloid (CVA), Magnetic resonance imaging (MRI), Nanovehicles, Single photon emission computed tomography (SPECT)",
author = "Jaruszewski, {Kristen M.} and Curran, {Geoffry L.} and Swaminathan, {Suresh K.} and Rosenberg, {Jens T.} and Grant, {Samuel C.} and Subramanian Ramakrishnan and Val Lowe and Poduslo, {Joseph F.} and Kandimalla, {Karunya K.}",
year = "2014",
month = "2",
doi = "10.1016/j.biomaterials.2013.10.075",
language = "English (US)",
volume = "35",
pages = "1967--1976",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Multimodal Nanoprobes to target cerebrovascular amyloid in Alzheimer's disease brain

AU - Jaruszewski, Kristen M.

AU - Curran, Geoffry L.

AU - Swaminathan, Suresh K.

AU - Rosenberg, Jens T.

AU - Grant, Samuel C.

AU - Ramakrishnan, Subramanian

AU - Lowe, Val

AU - Poduslo, Joseph F.

AU - Kandimalla, Karunya K.

PY - 2014/2

Y1 - 2014/2

N2 - Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries of the cortex and leptomeninges. CAA affects a majority of Alzheimer's disease (AD) patients and is associated with a rapid decline in cognitive reserve. Unfortunately, there is no pre-mortem diagnosis available for CAA. Furthermore, treatment options are few and relatively ineffective. To combat this issue, we have designed nanovehicles (nanoparticles-IgG4.1) capable of targeting cerebrovascular amyloid (CVA) and serving as early diagnostic and therapeutic agents. These nanovehicles were loaded with Gadolinium (Gd) based (Magnevist®) magnetic resonance imaging contrast agents or single photon emission computed tomography (SPECT) agents, such as 125I. In addition, the nanovehicles carry either anti-inflammatory and anti-amyloidogenic agents such as curcumin or immunosuppressants such as dexamethasone, which were previously shown to reduce cerebrovascular inflammation. Owing to the anti-amyloid antibody (IgG4.1) grafted on the surface, the nanovehicles are capable of specifically targeting CVA deposits. The nanovehicles effectively marginate from the blood flow to the vascular wall as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. They demonstrate excellent distribution to the brain vasculature and target CVA, thus providing MRI and SPECT contrast specific to the CVA in the brain. In addition, they also display the potential to carry therapeutic agents to reduce cerebrovascular inflammation associated with CAA, which is believed to trigger hemorrhage in CAA patients.

AB - Cerebral amyloid angiopathy (CAA) results from the accumulation of Aβ proteins primarily within the media and adventitia of small arteries and capillaries of the cortex and leptomeninges. CAA affects a majority of Alzheimer's disease (AD) patients and is associated with a rapid decline in cognitive reserve. Unfortunately, there is no pre-mortem diagnosis available for CAA. Furthermore, treatment options are few and relatively ineffective. To combat this issue, we have designed nanovehicles (nanoparticles-IgG4.1) capable of targeting cerebrovascular amyloid (CVA) and serving as early diagnostic and therapeutic agents. These nanovehicles were loaded with Gadolinium (Gd) based (Magnevist®) magnetic resonance imaging contrast agents or single photon emission computed tomography (SPECT) agents, such as 125I. In addition, the nanovehicles carry either anti-inflammatory and anti-amyloidogenic agents such as curcumin or immunosuppressants such as dexamethasone, which were previously shown to reduce cerebrovascular inflammation. Owing to the anti-amyloid antibody (IgG4.1) grafted on the surface, the nanovehicles are capable of specifically targeting CVA deposits. The nanovehicles effectively marginate from the blood flow to the vascular wall as determined by using quartz crystal microbalance with dissipation monitoring (QCM-D) technology. They demonstrate excellent distribution to the brain vasculature and target CVA, thus providing MRI and SPECT contrast specific to the CVA in the brain. In addition, they also display the potential to carry therapeutic agents to reduce cerebrovascular inflammation associated with CAA, which is believed to trigger hemorrhage in CAA patients.

KW - Alzheimer's disease (AD)

KW - Brain targeting

KW - Cerebrovascular amyloid (CVA)

KW - Magnetic resonance imaging (MRI)

KW - Nanovehicles

KW - Single photon emission computed tomography (SPECT)

UR - http://www.scopus.com/inward/record.url?scp=84890133352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890133352&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2013.10.075

DO - 10.1016/j.biomaterials.2013.10.075

M3 - Article

C2 - 24331706

AN - SCOPUS:84890133352

VL - 35

SP - 1967

EP - 1976

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 6

ER -